<DOC>
	<DOCNO>NCT01465464</DOCNO>
	<brief_summary>The purpose study compare overall survival ( OS ) Orantinib combination transcatheter arterial chemoembolization ( TACE ) versus placebo combination TACE patient unresectable hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description>This randomize , multi-center , double-blind , placebo-controlled phase III trial Orantinib administer combination TACE patient unresectable HCC . Patients randomly assign ( 1:1 ) receive TACE give combination either Orantinib ( 200 mg orally , twice per day ) placebo . ORIENTAL : ORantinib InvEstigatioN TAce combination triaL .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Orantinib</mesh_term>
	<criteria>Patients must diagnose HCC . Patients indication treatment curative hepatic resection curative percutaneous local therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . Patients able receive oral medication .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>